Axogen, Inc. (AXGN)
Data as of , from SEC Form 4 filings.
See up to 3 months of AXGN. The 7-day demo opens the 1M and 3M ranges and puts AXGN on your watchlist.
Start 7-day demoLatest AXGN insider trades
Joseph A. Tyndall - DirectorOpen-market sale$174K- Marc A. Began - OfficerOpen-market sale$3.20M
About Axogen, Inc. (AXGN)
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
- ALACHUA, FL
- 622
- 1986
- XNAS
AXGN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 98,503 | $4.66M |
| Option exercise | 4 | 161,706 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AXGN insider transactions (Form 4)
3844 Form 4 filings on record, the earliest from Jun 9, 2025, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael D. Dale - Officer | Grant or award | Restricted Stock Units | 98,000 | $0.00 | - | |
| Lindsey Marie Hartley - Officer | Grant or award | Common Stock | 17,500 | $0.00 | - | |
| Lindsey Marie Hartley - Officer | Tax withholding / forfeiture | Common Stock | 6,704 footnote F2 | $35.38 | $237K | |
| Lindsey Marie Hartley - Officer | Grant or award | Restricted Stock Units | 17,500 | $0.00 | - | |
| ||||||
| Marc A. Began - Officer | Grant or award | Common Stock | 22,500 footnote F1 | $0.00 | - | |
| ||||||
| Erick Wayne Devinney - Officer | Grant or award | Common Stock | 40,000 footnote F1 | $0.00 | - | |
| ||||||
| Michael D. Dale - Officer | Grant or award | Common Stock | 150,000 footnote F1 | $0.00 | - | |
| ||||||
 William P. Mr. Burke - Director | Open-market sale | Common Stock | 19,227 | $24.01 footnote F1 | $462K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 3,591 | $24.02 footnote F2 | $86K | |
| William P. Mr. Burke - Director | Option exercise | Stock Option (right to purchase) | 19,227 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Stock Option (right to purchase) | 3,591 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 19,227 | $8.14 | $157K | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 3,591 | $8.14 | $29K | |
| ||||||
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 11,431 | $24.05 footnote F1 | $275K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 5,347 | $24.01 footnote F2 | $128K | |
| William P. Mr. Burke - Director | Option exercise | Stock Option (right to purchase) | 11,431 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Stock Option (right to purchase) | 5,347 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 11,431 | $8.14 | $93K | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 5,347 | $8.14 | $44K | |
| ||||||
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 19,799 | $22.00 footnote F2 | $436K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 18,248 | $23.00 footnote F2 | $420K | |
| William P. Mr. Burke - Director | Option exercise | Stock Option (right to buy) | 20,436 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Stock Option (right to purchase) | 19,799 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Employee Stock Option (right to purchase) | 18,248 | $0.00 | - | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 20,436 | $6.30 | $129K | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 19,799 | $8.14 | $161K | |
| William P. Mr. Burke - Director | Option exercise | Common Stock | 18,248 | $7.04 | $128K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 20,436 | $19.15 footnote F1 | $391K | |
| ||||||
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 1,457 | $18.02 footnote F1 | $26K | |
| ||||||
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 736 | $18.00 footnote F1 | $13K | |
| ||||||
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 2,400 | $18.01 footnote F1 | $43K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 7,620 | $18.01 footnote F2 | $137K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 7,600 | $18.21 footnote F3,F4 | $138K | |
| William P. Mr. Burke - Director | Open-market sale | Common Stock | 14,571 | $18.21 footnote F4 | $265K | |
| ||||||
| Erick Wayne Devinney - Officer | Grant or award | Common Stock | 2,500 | $0.00 | - | |
| Erick Wayne Devinney - Officer | Open-market sale | Common Stock | 1,137 | $16.29 | $19K | |
| Paul Thomas - Director | Grant or award | Restricted Stock Units | 18,867 | $0.00 | - | |
 Guido J. Neels - Director | Open-market sale | Common Stock | 4,073 | $10.61 | $43K | |
Item 7.01, 9.01
Item 1.01, 7.01, 9.01
Item 1.01, 7.01, 8.01, 9.01
Item 2.02, 7.01, 9.01
Recent AXGN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JOSEPH A TYNDALL | Director | 3,500 | $175K | View on EDGAR | |
| AMY MCBRIDE-WENDELL | Director | 13,353 | $644K |
AXGN insider trading FAQ
What is the latest insider trade for AXGN?
Axogen, Inc. (AXGN) had 4 insider filings in the last 90 days, with the most recent on 2026-09-04. The full record for AXGN runs to 44 Form 4 filings, the earliest from 2025-06-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AXGN stock?
No insider purchases of AXGN were filed in the last 90 days.
How many insiders are selling AXGN stock?
4 insider sales of AXGN were filed in the last 90 days, totaling $4.66M.
Where can I see AXGN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AXGN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Joseph A. Tyndall view on EDGAR
- - Marc A. Began view on EDGAR
- - Amy McBride Wendell view on EDGAR
- - Kathy Johnson Weiler view on EDGAR
- - William P. Mr. Burke view on EDGAR
- - John Johnson view on EDGAR
- - Alan M. Levine view on EDGAR
- - Paul Thomas view on EDGAR
- - Joseph A. Tyndall view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AXGN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AXGN with a 7-day demo
- AXGN on your watchlist
- Every AXGN Form 4 filing on record
- Up to 3 months of AXGN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
